LI Yi-qing, MA Li-ping, DENG Cheng-xin. Combined Use of HDAC Inhibitors in the Treatment of Myeloid Associated Tumor Curative Effect Is Poor[J]. Journal of Evidence-Based Medicine, 2017, 17(2): 78-80. DOI: 10.12019/j.issn.1671-5144.2017.02.005
|
Citation:
|
LI Yi-qing, MA Li-ping, DENG Cheng-xin. Combined Use of HDAC Inhibitors in the Treatment of Myeloid Associated Tumor Curative Effect Is Poor[J]. Journal of Evidence-Based Medicine, 2017, 17(2): 78-80. DOI: 10.12019/j.issn.1671-5144.2017.02.005
|
LI Yi-qing, MA Li-ping, DENG Cheng-xin. Combined Use of HDAC Inhibitors in the Treatment of Myeloid Associated Tumor Curative Effect Is Poor[J]. Journal of Evidence-Based Medicine, 2017, 17(2): 78-80. DOI: 10.12019/j.issn.1671-5144.2017.02.005
|
Citation:
|
LI Yi-qing, MA Li-ping, DENG Cheng-xin. Combined Use of HDAC Inhibitors in the Treatment of Myeloid Associated Tumor Curative Effect Is Poor[J]. Journal of Evidence-Based Medicine, 2017, 17(2): 78-80. DOI: 10.12019/j.issn.1671-5144.2017.02.005
|
DownLoad: